SI3059239T1 - SULFURIC CONTAINING BICYCLIC COMPOUNDS - Google Patents
SULFURIC CONTAINING BICYCLIC COMPOUNDS Download PDFInfo
- Publication number
- SI3059239T1 SI3059239T1 SI201430780T SI201430780T SI3059239T1 SI 3059239 T1 SI3059239 T1 SI 3059239T1 SI 201430780 T SI201430780 T SI 201430780T SI 201430780 T SI201430780 T SI 201430780T SI 3059239 T1 SI3059239 T1 SI 3059239T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compound
- salt
- dimethylcyclohexyl
- methyl
- group
- Prior art date
Links
- -1 bicyclic compound Chemical class 0.000 title claims abstract 9
- 229910052717 sulfur Inorganic materials 0.000 title claims abstract 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 title abstract 4
- 239000011593 sulfur Substances 0.000 title abstract 4
- 208000019901 Anxiety disease Diseases 0.000 claims abstract 4
- 208000028698 Cognitive impairment Diseases 0.000 claims abstract 4
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract 4
- 208000001914 Fragile X syndrome Diseases 0.000 claims abstract 4
- 208000008238 Muscle Spasticity Diseases 0.000 claims abstract 4
- 208000002193 Pain Diseases 0.000 claims abstract 4
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract 4
- 208000010877 cognitive disease Diseases 0.000 claims abstract 4
- 201000000980 schizophrenia Diseases 0.000 claims abstract 4
- 208000018198 spasticity Diseases 0.000 claims abstract 4
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- BHUJNLVJCZQZIK-UHFFFAOYSA-N 1-[[6-(4,4-dimethylcyclohexyl)-2-methylthieno[2,3-d]pyrimidin-4-yl]methyl]-2,2-dimethylpiperidin-4-ol Chemical compound Cc1nc(CN2CCC(O)CC2(C)C)c2cc(sc2n1)C1CCC(C)(C)CC1 BHUJNLVJCZQZIK-UHFFFAOYSA-N 0.000 claims 2
- WQNFGCPWKUMCFW-UHFFFAOYSA-N 1-[[6-(4,4-dimethylcyclohexyl)-2-methylthieno[2,3-d]pyrimidin-4-yl]methyl]piperidin-4-ol Chemical compound Cc1nc(CN2CCC(O)CC2)c2cc(sc2n1)C1CCC(C)(C)CC1 WQNFGCPWKUMCFW-UHFFFAOYSA-N 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- JXMFNTQQCVNKRZ-UHFFFAOYSA-N 2-methylthieno[2,3-d]pyrimidine Chemical compound CC1=NC=C2C=CSC2=N1 JXMFNTQQCVNKRZ-UHFFFAOYSA-N 0.000 claims 1
- PNVNPTXJWNZGSS-UHFFFAOYSA-N 4-[[6-(4,4-dimethylcyclohexyl)-2-methylthieno[2,3-d]pyrimidin-4-yl]methyl]-3,3-dimethylmorpholine Chemical compound Cc1nc(CN2CCOCC2(C)C)c2cc(sc2n1)C1CCC(C)(C)CC1 PNVNPTXJWNZGSS-UHFFFAOYSA-N 0.000 claims 1
- OCJTUWZMTIIGSY-UHFFFAOYSA-N 6-(4,4-dimethylcyclohexyl)-2-methyl-4-(thiomorpholin-4-ylmethyl)thieno[2,3-d]pyrimidine Chemical compound Cc1nc(CN2CCSCC2)c2cc(sc2n1)C1CCC(C)(C)CC1 OCJTUWZMTIIGSY-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229940126027 positive allosteric modulator Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013216332 | 2013-10-17 | ||
| EP14853825.9A EP3059239B1 (en) | 2013-10-17 | 2014-10-17 | Sulfur-containing bicyclic compound |
| PCT/JP2014/077653 WO2015056771A1 (ja) | 2013-10-17 | 2014-10-17 | 含硫黄二環式化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3059239T1 true SI3059239T1 (en) | 2018-08-31 |
Family
ID=52826697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430780T SI3059239T1 (en) | 2013-10-17 | 2014-10-17 | SULFURIC CONTAINING BICYCLIC COMPOUNDS |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9051339B2 (enExample) |
| EP (1) | EP3059239B1 (enExample) |
| JP (1) | JP6477484B2 (enExample) |
| KR (1) | KR102248450B1 (enExample) |
| CN (1) | CN105636965B (enExample) |
| AR (1) | AR098070A1 (enExample) |
| AU (1) | AU2014335304B2 (enExample) |
| BR (1) | BR112016008654B8 (enExample) |
| CA (1) | CA2927518C (enExample) |
| CY (1) | CY1120880T1 (enExample) |
| DK (1) | DK3059239T3 (enExample) |
| EA (1) | EA029075B1 (enExample) |
| ES (1) | ES2685070T3 (enExample) |
| HR (1) | HRP20181183T1 (enExample) |
| HU (1) | HUE040208T2 (enExample) |
| IL (1) | IL244953B (enExample) |
| LT (1) | LT3059239T (enExample) |
| MX (1) | MX367857B (enExample) |
| MY (1) | MY177271A (enExample) |
| NZ (1) | NZ719149A (enExample) |
| PH (1) | PH12016500625B1 (enExample) |
| PL (1) | PL3059239T3 (enExample) |
| PT (1) | PT3059239T (enExample) |
| RS (1) | RS57532B1 (enExample) |
| SA (1) | SA516370956B1 (enExample) |
| SG (1) | SG11201602926UA (enExample) |
| SI (1) | SI3059239T1 (enExample) |
| SM (1) | SMT201800431T1 (enExample) |
| TW (1) | TWI648281B (enExample) |
| UA (1) | UA116042C2 (enExample) |
| WO (1) | WO2015056771A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| WO2019155765A1 (ja) | 2018-02-06 | 2019-08-15 | 株式会社瑞光 | 伸縮シート及び伸縮シートを用いた使い捨て着用物品、並びにそれらの製造方法 |
| MX2021002385A (es) * | 2018-08-31 | 2021-04-29 | Astellas Pharma Inc | Composicion farmaceutica para administracion oral. |
| WO2022029666A1 (en) | 2020-08-05 | 2022-02-10 | Richter Gedeon Nyrt. | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES |
| WO2023028519A2 (en) * | 2021-08-27 | 2023-03-02 | Astellas Pharma Global Development, Inc. | Methods of treating substance use disorder |
| JP2025157626A (ja) * | 2022-09-01 | 2025-10-16 | アステラス製薬株式会社 | ６－（４，４－ジメチルシクロヘキシル）－４－［（１，１－ジオキソ－１λ６－チオモルホリン－４－イル）メチル］－２－メチルチエノ［２，３－ｄ］ピリミジンまたはその塩の製造方法 |
| WO2024217531A1 (zh) * | 2023-04-21 | 2024-10-24 | 西藏海思科制药有限公司 | Cyp11a1抑制剂及其用途 |
| CN117263951A (zh) * | 2023-09-13 | 2023-12-22 | 广东莱佛士制药技术有限公司 | 6-溴-2-甲基噻吩并[2,3-d]嘧啶-4-甲腈的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
| WO2002062803A1 (en) | 2001-02-08 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Thienopyrimidine derivative |
| JP2002308882A (ja) * | 2001-02-08 | 2002-10-23 | Yamanouchi Pharmaceut Co Ltd | チエノピリミジン誘導体 |
| WO2004089312A2 (en) * | 2003-03-31 | 2004-10-21 | Predix Pharmaceuticals Holdings, Inc. | New piperidinylamino-thieno[2,3-d] pyrimidine compounds |
| US7723324B2 (en) * | 2003-10-28 | 2010-05-25 | Sepracor, Inc. | Imidazo[1,2-A]pyridine anxiolytics |
| GB0416168D0 (en) | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1828199B1 (en) * | 2004-12-17 | 2009-05-06 | F. Hoffmann-Roche AG | Thieno-pyridine derivatives as gaba-b allosteric enhancers |
| US8802670B2 (en) | 2006-04-26 | 2014-08-12 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| ES2665277T3 (es) | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Análogos de purina y su uso como agentes inmunosupresores |
| CA2773131C (en) * | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
-
2014
- 2014-10-16 TW TW103135823A patent/TWI648281B/zh not_active IP Right Cessation
- 2014-10-17 EA EA201690790A patent/EA029075B1/ru not_active IP Right Cessation
- 2014-10-17 SI SI201430780T patent/SI3059239T1/en unknown
- 2014-10-17 AR ARP140103875A patent/AR098070A1/es active IP Right Grant
- 2014-10-17 CN CN201480057239.0A patent/CN105636965B/zh not_active Expired - Fee Related
- 2014-10-17 BR BR112016008654A patent/BR112016008654B8/pt active IP Right Grant
- 2014-10-17 SG SG11201602926UA patent/SG11201602926UA/en unknown
- 2014-10-17 RS RS20180865A patent/RS57532B1/sr unknown
- 2014-10-17 LT LTEP14853825.9T patent/LT3059239T/lt unknown
- 2014-10-17 HU HUE14853825A patent/HUE040208T2/hu unknown
- 2014-10-17 CA CA2927518A patent/CA2927518C/en active Active
- 2014-10-17 AU AU2014335304A patent/AU2014335304B2/en not_active Ceased
- 2014-10-17 KR KR1020167011628A patent/KR102248450B1/ko active Active
- 2014-10-17 NZ NZ71914914A patent/NZ719149A/en not_active IP Right Cessation
- 2014-10-17 SM SM20180431T patent/SMT201800431T1/it unknown
- 2014-10-17 UA UAA201605245A patent/UA116042C2/uk unknown
- 2014-10-17 MX MX2016004944A patent/MX367857B/es active IP Right Grant
- 2014-10-17 DK DK14853825.9T patent/DK3059239T3/en active
- 2014-10-17 JP JP2015542677A patent/JP6477484B2/ja not_active Expired - Fee Related
- 2014-10-17 ES ES14853825.9T patent/ES2685070T3/es active Active
- 2014-10-17 PT PT14853825T patent/PT3059239T/pt unknown
- 2014-10-17 HR HRP20181183TT patent/HRP20181183T1/hr unknown
- 2014-10-17 PL PL14853825T patent/PL3059239T3/pl unknown
- 2014-10-17 US US14/517,229 patent/US9051339B2/en active Active
- 2014-10-17 MY MYPI2016701379A patent/MY177271A/en unknown
- 2014-10-17 WO PCT/JP2014/077653 patent/WO2015056771A1/ja not_active Ceased
- 2014-10-17 EP EP14853825.9A patent/EP3059239B1/en active Active
-
2015
- 2015-04-17 US US14/689,748 patent/US9642852B2/en not_active Expired - Fee Related
-
2016
- 2016-04-06 IL IL244953A patent/IL244953B/en active IP Right Grant
- 2016-04-06 PH PH12016500625A patent/PH12016500625B1/en unknown
- 2016-04-16 SA SA516370956A patent/SA516370956B1/ar unknown
-
2018
- 2018-08-14 CY CY20181100858T patent/CY1120880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3059239T1 (en) | SULFURIC CONTAINING BICYCLIC COMPOUNDS | |
| PH12015500347A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| MD4602B1 (ro) | Inhibitori ai virusului hepatic C | |
| MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| NZ631762A (en) | 5-membered heteroaryls and their use as antiviral agents | |
| MD20150092A2 (ro) | Derivate ale amidelor pentru tratamentul infecţiei cu HIV | |
| MX2014001481A (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio. | |
| AR084824A1 (es) | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas | |
| PE20160204A1 (es) | Compuestos y composiciones como inhibidores de la mek | |
| SI2738156T1 (en) | TETRACYCLINE COMPOSITE SUBSTITUTED WITH 9-AMINOMETHYL | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| MD20150075A2 (ro) | Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale | |
| MY170262A (en) | Dicarboxylic acid compound | |
| AR105774A1 (es) | Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico | |
| IN2014MN01521A (enExample) | ||
| PH12014502180A1 (en) | Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| PH12015500009B1 (en) | Phenoxyethyl piperidine compounds | |
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| PH12017501652A1 (en) | Kv1.3 inhibitors and their medical application | |
| MX348979B (es) | Agente de control de enfermedades de las plantas. | |
| PE20141168A1 (es) | Derivados de pirazolidin-3-ona | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| BR112016006865A2 (pt) | berberinas substituídas e suas sínteses |